Development of a mathematical model that predicts the outcome of hormone therapy for prostate cancer

Journal of Theoretical Biology

Volumn 264, Issue 2, 2010, Pages 517-527

  Hirata, Yoshito ^a,b   Bruchovsky, Nicholas ^c   Aihara, Kazuyuki ^a,b  

^a JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^b INSTITUTE OF INDUSTRIAL SCIENCE   (Japan)

^c VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

Androgen independence; Intermittent androgen suppression; Mathematical model; Progression

Indexed keywords

ANDROGEN; CYPROTERONE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ANDROGEN; ANTIGEN; CANCER; DISEASE TREATMENT; EXPERIMENTAL STUDY; HORMONE; NUMERICAL MODEL; PREDICTION; TESTOSTERONE;

ANTIANDROGEN THERAPY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PREVENTION; CANCER RELAPSE; CLINICAL TRIAL; DRUG INTERMITTENT THERAPY; HUMAN; MATHEMATICAL MODEL; MOLECULAR DYNAMICS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; STATISTICAL MODEL; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; VALIDITY;

ALGORITHMS; ANDROGEN ANTAGONISTS; DISEASE PROGRESSION; HUMANS; MALE; MODELS, THEORETICAL; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 77951652729     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2010.02.027     Document Type: Article

References (37)

1. Abonyi J., Babuska R., Verbruggen H.B., Szeifert F. Incorporating prior knowledge in fuzzy model identification. Int. J. Systems Sci. 2000, 31:657-667.
2. Abrahamsson P.-A. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Eur. Urol. 2010, 57:49-59.
3. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate-specific antigen. Cancer 1993, 71:2782-2790.
4. Boccon-Gibod L., Hammerrer P., Madersbacher S., Mottet N., Prayer-Galetti T., Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int. 2007, 100:738-742.
5. Bruchovsky N., Brown E.M., Coppin C.M., Goldenberg S.L., Le Riche J.C., Murray N.C., Rennie P.S. The endocrinology and treatment of prostate tumor progression. Prog. Clin. Biol. Res. 1987, 239:347-387.
6. Bruchovsky N., Klotz L., Crook J., Malone S., Ludgate C., Morris W.J., Geave M.E., Gooldenberg S.L. Final results of the Canadian prospective phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: clinical parameters. Cancer 2006, 107:389-395.
7. Bruchovsky N., Klotz L., Crook J., Goldenberg S.L. Locally Advanced prostate cancer: biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007, 109:858-867.
8. Bruchovsky N., Klotz L., Crook J., Phillips N., Abersbach J., Goldenberg L.S. Quality of life, morbidity and mortality results from a prospective phase II study of intermittent androgen suppression for men with evidence of PSA relapse after radiotherapy for locally advanced prostate cancer. Clin. Genitourinary Cancer 2008, 6:46-52.
9. Byrne H.M., Alarcon T., Owen M.R., Webb S.D., Maini P.K. Modelling aspects of cancer dynamics: a review. Philos. Trans. R. Soc. Lond. Ser. A Math. Phys. Eng. Sci. 2006, 364:1563-1578.
10. De La Taille A., Zerbib M., Conquy S., Amsellem-Ouazana D., Thiounn N., Flam T.A., Debre B. Intermittent androgen suppression in patients with prostate cancer. BJU Int. 2003, 91:18-22.
11. The Prostate as an Endocrine Gland 1989, CRC Press, Inc, Boca Raton. W.E. Farnsworth, R.J. Ablin (Eds.).
12. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
13. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D., Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 1995, 45:839-845.
14. Grossfeld G.D., Chaudhary U.B., Reese D.M., Carroll P.R., Small E.J. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 2001, 58:240-245.
15. Ideta A.M., Tanaka G., Takeuchi T., Aihara K. A mathematical model of intermittent androgen suppression remedy for prostate cancer. J. Nonlinear Sci. 2008, 18:593-614.
16. Jackson T.L. A mathematical model of prostate tumor growth and androgen-independent relapse. Discrete Contin. Dyn. Syst. Ser. B 2004, 4:187-201.
17. Jackson T.L. A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data. Neoplasia 2004, 6:697-704.
18. Johansen T.A. Identification of non-linear systems using empirical data and prior knowledge: an optimization approach. Automatica J. IFAC 1996, 32:337-356.
19. Judd K., Mees A. On selecting models for nonlinear time series. Physica D 1995, 82:426-444.
20. Malone S., Perry G., Eapen L., Segal R., Gallant V., Dahrouge S., Crook J., Spaans J.N. Mature results of the Ottawa phase II study of intermittent androgen-suppression therapy in prostate cancer: clinical predictors of outcome. Int. J. Radiat. Oncol. Biol. Phys. 2007, 68:669-706.
21. Michor F., Hughes T.P., Iwasa Y., Branford S., Shah N.P., Sawyers C.L., Nowak M.A. Dynamics of chronic myeloid leukaemia. Nature 2005, 435:1267-1270.
22. Nakamura T., Judd K., Mees A.I., Small M. A comparative study of information criteria for model selection. Int. J. Bifur. Chaos Appl. Sci. Eng. 2006, 16:2153-2175.
23. Nepomuceno E.G., Takahashi R.H.C., Aguirre L.A., Neto O.M., Mendes E.M.A.M. Multiobjective nonlinear system identification: a case study with thyristor controlled series capacitor (TCSC). Int. J. Systems Sci. 2000, 35:537-546.
24. Noble R.L. Production of Nb rat carcinoma of the dorsal prostate and response of estrogen-dependent transplants to sex hormones and tamoxifen. Cancer Res. 1980, 40:3547-3550.
25. Nowak M.A., Michor F., Iwasa Y. The linear process of somatic evolution. Proc. Natl. Acad. Sci. USA 2003, 100:14966-14969.
26. Peyromaure M., Delongchamps N.B., Debre B., Zerbib M. Intermittent androgen deprivation for biologic recurrence after radical prostatectomy: long-term experience. Urology 2005, 65:724-729.
27. Price K.V., Storn R.M., Lampinen J.A. Differential evolution: a practical approach to global optimization 2005, Springer-Verlag, Berlin., We used part of program at 〈http://www.icsi.berkeley.edu/storn/code.html〉.
28. Rennie P., Read J., Murphy L. Hormones and cancer. The Basic Science of Oncology 2005, 400-430. McGraw-Hill, New York. I.F. Tannock, R.P. Hill, R.G. Bristow, L. Harrington (Eds.).
29. Rissanen J. MDL denoising. IEEE Trans. Inf. Theory 2000, 46:2537-2543.
30. Sato N., Akakura K., Isaka S., Nakatsu H., Tanaka M., Ito H., Masai M. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology 2004, 64:341-345.
31. Scholz M., Lam R., Strum S., Jennrich R., Johnson H., Trilling T. Prostate cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone inactivating pharmaceuticals. Urology 2007, 70:506-510.
32. Seruga B., Tannock I.F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat. Clin. Pract. Oncol. 2008, 5:574-576.
33. Shaw G.L., Wilson P., Cuzick J., Prowse D.M., Goldenberg S.L., Spry N.A., Oliver T. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. BJU Int. 2007, 19:1056-1065.
34. Shimada T., Aihara K. A nonlinear model with competition between prostate tumor cells and its application to intermittent androgen suppression therapy of prostate cancer. Math. Biosci. 2008, 214:134-139.
35. Sontag E.D. For differential equations with r parameters, 2r+1 experiments are enough for identification. J. Nonlinear Sci. 2002, 12:553-583.
36. Tanaka G., Tsumoto K., Tsuji S., Aihara K. Bifurcation analysis on a hybrid systems model of intermittent hormonal therapy for prostate cancer. Physica D 2008, 237:2616-2627.
37. Tulleken H.J.A.F. Grey-box modelling and identification using physical knowledge and Bayesian techniques. Automatica J. IFAC 1993, 29:285-308.